

Medicines Optimisation Position Statement

Position Statement	Continuous Glucose Monitoring (CGM) in pregnancy.
Position Statement number	019
Approved by Medicines Optimisation Group:	August 2023
Ratified by Medicines Board	September 2023
Date of issue:	September 2023
Date of last review:	n/a
Date of planned review	September 2025 or reviewed in the light of new national

Background

CGM is available to pregnant women with diabetes to help meet pregnancy blood glucose targets and improve neonatal outcomes, in line with NICE.¹

CGM use and pregnancy.

The use of a CGM device is available for:

- Pregnant patients living with type 1 diabetes.
- Pregnant patients with learning disabilities.
- Pregnant women who are on insulin therapy but do not have type 1 diabetes if they have:
 - problematic severe hypoglycaemia (with or without impaired awareness of hypoglycaemia) or
 - they have unstable blood glucose levels.

CGM use is for the duration of pregnancy only. If pregnant women fall under policy [MOG 15](#) they may continue to use CGM after pregnancy.

References:

Diabetes in pregnancy: management from preconception to the postnatal period
<https://www.nice.org.uk/guidance/ng3>